Overview

Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, two-arm, double-blind study of efficacy and safety of Q8003 in patients who have undergone primary unilateral total knee arthroplasty

Phase:

Phase 3

Details

Lead Sponsor:

QRxPharma Inc.

Treatments:

Morphine
Oxycodone